In HNSCC neoadjuvant interventions, OX40 agonism demonstrates capacity to expand CD103+CD39+ tumour-antigen-specific CD8+ TILs, albeit with a response incidence of merely 25% [102]. The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.